2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Investor Profile Country Deals
Fidelity Biosciences Group United States 20
MPM Asset Management LLC United States 20
Pappas Ventures United States 20
Polaris Venture Partners Inc Multistage venture capital investors with focus Technology, Healthcare and Consumer United States 20
Johnson & Johnson Development Corp Inc United States 19
Sutter Hill Ventures United States 19
BioAdvance - Biotechnology Greenhouse Corporation of Southeastern Pennsylvania United States 18
Delphi Ventures Inc Venture capital firm with a focus on early stage investing in medical devices and biotechnology United States 18
Flagship Ventures Venture capital firm United States 18
Quaker BioVentures Inc United States 18
Novartis Venture Funds The corporate venturing arm of Novartis. Switzerland 17
Thomas McNerney & Partners LLC Healthcare venture firm. United States 17
Canaan Partners Venture capital firm with a focus on early stage technology and healthcare companies United States 16
Clarus Ventures LLC Life sciences venture capital firm United States 16
HBM BioVentures AG Switzerland 16
Montreux Equity Partners United States 16
NGN Capital United States 16
One Liberty Ventures United States 16
ProQuest Investments United States 16
Prospect Venture Partners Venture capital firm United States 16

Pages

Selected funding rounds

Date Company Profile Round Ccy Amount
Aug 2012 Micro Interventional Devices Inc Developer of disruptive technologies for use in percutaneous and minimally invasive structural heart repair Debt
Jul 2012 Juventas Therapeutics Inc Series B
Jul 2012 Juventas Therapeutics Inc Series B
Jul 2012 Coferon Inc Develops orally active drugs that act like small drug molecules, can permeate cell membranes, and once inside, can assemble into larger molecules Series B
Jul 2012 Coferon Inc Develops orally active drugs that act like small drug molecules, can permeate cell membranes, and once inside, can assemble into larger molecules Series B
Jul 2012 Coferon Inc Develops orally active drugs that act like small drug molecules, can permeate cell membranes, and once inside, can assemble into larger molecules Series B
Jul 2012 Juventas Therapeutics Inc Series B
Jul 2012 Juventas Therapeutics Inc Series B
18 Jun 2012 Oxford Immunotec Ltd Venture USD 28,000,000
Jun 2012 InnoPharma LLC N/A
Jun 2012 Gemmus Pharma Inc Developer of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases. Series A
Jun 2012 InnoPharma LLC N/A
Jun 2012 Auxogyn Inc Series B
Jun 2012 Ceptaris Therapeutics Inc Specialty pharmaceuticals company. Series D
Jun 2012 Santaris Pharma AS Venture
Jun 2012 Santaris Pharma AS Venture
Jun 2012 Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Debt
Jun 2012 Santaris Pharma AS Venture
Jun 2012 Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Debt
Jun 2012 Santaris Pharma AS Venture

Pages

Selected acquisitions

Date Company Profile Country Ccy Amount
21 Jul 1999 Centocor Inc United States
12 Jul 1999 Perclose Inc United States
14 Apr 1998 VacTex Inc
24 Feb 1998 Somatogen Inc A biopharmaceutical company developing synthetic hemoglobin products for use in blood transfusion. United States
Memory Pharmaceuticals Corp United States
Inpharmatica Ltd United Kingdom

Pages

Selected companies

Company type: 
Developer of compound for the treatment of multiple sclerosis.
Company type: 
Developer of high value proteins and oil body based products for personal care, nutrition and pharmaceutical industries.
Company type: 
Specialty pharmaceutical company developing local minimally-invasive drug-device convergence products.
Company type: 
Publicly traded biopharmaceutical company focused on developing and commercializing novel treatments in oncology.
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products